The Company is developing new anti myopia drugs with the support of the Biotechnology Integrated Incubation Center (Si2C) and the Price Creation Program of the Ministry of Science and Technology. The aim is to develop a new generation of eye drops to treat increased myopia in children. In addition, the company has extended its research and development technology to develop a new generation of eye drops for the treatment of dry eye syndrome, and aims to continue developing new nucleic acid drugs for the treatment of other eye surface diseases in the future.
HISTORY
The Company was established in 2019 and is headquartered in Kaohsiung city, Taiwan.
Headquarters
No.66,3F-5, Sanchong Rd Nangang Dist
Taipei City; Taipei City;
Contact Details: Purchase the Sunhawk Vision Biotech Inc. report to view the information.
Website: http://www.sunhawkvision.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service